Slide 1: Valneva's Full Year 2024 Results and Business Update
Valneva’s Full Year 2024 Results and Business Update March 20, 2025
Slide 2: Disclaimer
Disclaimer This presentation does not contain or constitute an offer of, or the solicitation of an facts but are forward-looking statements, including statements with respect to financial offer to buy or subscribe for, Valneva SE shares to any person in the USA or in any guidance, cash flows and cap
Slide 3: Agenda
Agenda Introduction Business Update Financial Report FY 2024 Financial Outlook Value Drivers Q&A Valneva – FY 2024 Analyst Presentation 3
Slide 4: Full Year 2024 Key Highlights
Full Year 2024 Key Highlights 13% YoY Sales Growth Solid Cash Position €163.3m €168.3m Aligned with 2024 guidance 67% lower operating cash burn Successful €57m financing FY 2024 Strong Regulatory Pipeline Optimization Execution Leading Phase 2 Shigella 3 additional IXCHIQ® approvals; Program upcomin
Slide 5: Execution in 2024 Sets the Stage for Multiple 2025 Milestones
Execution in 2024 Sets the Stage for Multiple 2025 Milestones Substantial Multiple Anticipated Clinical & Regulatory Data Readouts, Progress Product Approvals Financial Strength Label Extensions Significantly expanded access to IXCHIQ® Transformative potential: VLA15 Phase 3 Study − Launch
Slide 6: Valneva Outlook: Growth Drivers for 2025 and Beyond
Valneva Outlook: Growth Drivers for 2025 and Beyond VLA15 success case • Potential for sustained profitability upon potential approval and commercialization*, driven by substantial milestones and royalties starting in 2027 Growing commercial revenues • Near term: continued growth trajectory of IXIAR
Slide 7: Agenda
Agenda Introduction Business Update Financial Report FY 2024 Financial Outlook Value Drivers Q&A Valneva – FY 2024 Analyst Presentation 7
Slide 8: World's leading Lyme Disease Vaccine Candidate
World’s leading Lyme Disease Vaccine Candidate VLA15
Slide 9: Lyme Disease Represents a Major Medical Need and Market Opportunity
Lyme Disease Represents a Major Medical Need and Market Opportunity No vaccine is currently available to prevent Lyme disease in humans Annual Burden of Disease Commercial opportunity for Valneva U.S.1 Europe2 U.S. Europe ~476K cases >129K cases 87 million 202 million Severe Manifestations3 Populati
Slide 10: Phase 3: First Data Readout Expected at the End of 2025
Phase 3: First Data Readout Expected at the End of 2025 Pfizer aims to submit regulatory applications in U.S. and Europe in 20261 Population: ~9,400 evaluable participants ≥5 years of age at high risk of Lyme disease (LD) (by residence and occupational/recreational activities) in U.S., Canada and
Slide 11: The World's First Chikungunya Vaccine
The World’s First Chikungunya Vaccine IXCHIQ® / VLA1553 IXCHIQ® is currently approved by the U.S. Food & Drug Administration (FDA), European Medicines Agency (EMA), The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada for the prevention of disease caused by chikungun
Slide 12: IXCHIQ Builds on Key Differentiators to Drive Growth
IXCHIQ® Builds on Key Differentiators to Drive Growth The 1st vaccine against chikungunya providing a strong and persistent immune response with only one dose 98.9% seroresponse rate at Day 29 - Sustained seroresponse rate at 96% after three years1 Strong and persistent immune response in adu
Slide 13: IXCHIQ: Focused on Expanding Access, Label Extension, Product Profile
IXCHIQ®: Focused on Expanding Access, Label Extension, Product Profile Robust clinical program supported by new $43.1 million CEPI grant1 Post-Marketing Effectiveness2 (Phase 4) To confirm effectiveness following licensure based on an immunological surrogate of protection and to optimize description
Slide 14: World's Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate S4V2
Slide 15: S4V2: Opportunity to Develop First-in-Class Vaccine for a Life-Threatening Disease
S4V2: Opportunity to Develop First-in-Class Vaccine for a Life-Threatening Disease Tetravalent bioconjugate vaccine with potential to cover up to ~85% of shigellosis infections1 Vaccine Highlights Market Opportunity Upcoming Milestones • World’s most clinically advanced tetravalent • Global market e
Slide 16: Novel Zika Virus Vaccine Candidate
Novel Zika Virus Vaccine Candidate VLA1601
Slide 17: VLA1601: Optimized Vaccine Candidate Against Zika Virus
VLA1601: Optimized Vaccine Candidate Against Zika Virus Phase 1 results expected this year Vaccine Highlights Market Opportunity Upcoming Milestones • Flaviviral disease transmitted by • Execute Phase 1 clinical trial with • Novel adjuvanted inactivated whole- Aedes mosquitoes2 enhanced process and
Slide 18: Valneva Commercial Business
Valneva Commercial Business
Slide 19: Agenda
Agenda Introduction Business Update Financial Report FY 2024 Financial Outlook Value Drivers Q&A Valneva – FY 2024 Analyst Presentation 19
Slide 20: FY 2024 Financials: Product Sales of €163.3 million
FY 2024 Financials: Product Sales of €163.3 million Commercial business showing continued, significant growth €m (audited) FY FY % % 2024 2023 Change at CER* IXIARO®/JESPECT® 94.1 73.5 +28% +27% DUKORAL® 32.3 29.8 +8% +9% IXCHIQ® 3.7 -- -- -- Third party products 33.2 35.7 -7% -8% Total product sale
Slide 21: FY 2024 Financials: Income Statement
FY 2024 Financials: Income Statement €m (audited) FY 2024 FY 2023 Product sales 163.3 144.6 Other Revenues 6.3 9.1 Revenues 169.6 153.7 Cost of goods and services (98.5) (100.9) Research and development expenses (74.1) (59.9) Marketing and distribution expenses (52.4) (48.8) General and administrati
Slide 22: Agenda
Agenda Introduction Business Update Financial Report FY 2024 Financial Outlook Value Drivers Q&A Valneva – FY 2024 Analyst Presentation 22
Slide 23: Valneva Remains Solidly Funded with Strong Financial Outlook
Valneva Remains Solidly Funded with Strong Financial Outlook 2025 Guidance Financial Outlook Product Sales: €170 - €180 million1; Commercial Continued revenue growth and cash flows from business expected to be cash-flow positive commercialized vaccines Total Revenues: €180 - €190 million Foc
Slide 24: Agenda
Agenda Introduction Business Update Financial Report FY 2024 Financial Outlook Value Drivers Q&A Valneva – FY 2024 Analyst Presentation 24
Slide 25: Valneva Outlook: Growth Drivers for 2025 and Beyond
Valneva Outlook: Growth Drivers for 2025 and Beyond VLA15 success case • Potential for sustained profitability upon potential approval and commercialization*, driven by substantial milestones and royalties starting in 2027 Growing commercial revenues • Near term: continued growth trajectory of IXIAR
Slide 26: Agenda
Agenda Introduction Business Update Financial Report FY 2024 Financial Outlook Value Drivers Q&A Valneva – FY 2024 Analyst Presentation 26
Slide 27: Thank you
Thank you Merci Danke Tack valneva